Professor Lanping Xu: Joining Forces in the Greater Bay Area to Build a New Platform for Hematology Exchange Across the Mainland, Taiwan, Hong Kong, and Macao | 2026 Cross-Strait Hematology Conference%
In the golden autumn season, colleagues from across the mountains and seas came together. The 2026 Cross-Strait Hematology Conference was held in Zhuhai, Guangdong, on August 21–22, bringing together hematology experts and scholars from the Chinese mainland, Taiwan, Hong Kong, and Macao to engage in in-depth discussions on advances in the field, clinical practice, and nursing innovation. During the conference, Professor Lanping Xu of Peking University People's Hospital, Chair of the Hematology Committee of the Cross-Strait Medical and Health Exchange Association and Conference Chair, spoke with the media about the conference agenda, complementary strengths in hematopoietic stem cell transplantation across the mainland and Taiwan, and the long-term value of the academic platform.
the 14th Lu Daopei Hematology Forum丨Professor Xian Zhang: Reshaping the Treatment Landscape Through Precision Stratification — Advances in Immunotherapy for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
On August 21, 2026, the 14th Lu Daopei Hematology Forum officially opened at Hebei Yanda Lu Daopei Hospital. Over the past 14 years, the conference has built a strong academic foundation. This year's meeting focused on cutting-edge topics including hematopoietic stem cell transplantation, cellular immunotherapy, and precision diagnosis and treatment of hematologic diseases, bringing together experts and scholars from across China to discuss advances in the field. During the conference, Oncology Frontier – Hematology Frontier invited Professor Xian Zhang of Hebei Yanda Lu Daopei Hospital for an interview. He shared his insights into the evolving treatment landscape of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), the timing and clinical value of immunotherapy, and strategies for managing treatment-resistant and relapsed disease.
the 14th Lu Daopei Hematology Forum丨Professor Yuzhu Shi: Identifying Etiology Through Imaging for Precise Diagnosis — Imaging Diagnosis of Central Nervous System Infections After Hematopoietic Stem Cell Transplantation
On August 21, 2026, the 14th Lu Daopei Hematology Forum officially opened at Hebei Yanda Lu Daopei Hospital. Over the past 14 years, the conference has established a strong academic foundation. This year's meeting focused on cutting-edge topics including hematopoietic stem cell transplantation, cellular immunotherapy, and precision diagnosis and treatment of hematologic diseases, bringing together experts and scholars from across China to discuss advances in the field. During the conference, Oncology Frontier – Hematology Frontier invited Professor Yuzhu Shi from Lu Daopei Hospital for an interview. He shared his insights into the pathogen characteristics of central nervous system (CNS) infections after hematopoietic stem cell transplantation (HSCT), key imaging features for differential diagnosis, and the clinical value and future development of imaging technologies.
2026 Pujiang Urological Oncology Conference丨Professor Gang Zhu: AI and Holographic Imaging Empower Urologic Oncology Surgery — From Precision Resection to Functional Preservation
The 2026 Pujiang Urological Oncology Conference was held in Shanghai, bringing together experts from China and abroad to discuss standardized diagnosis and treatment, innovations in surgical techniques, and advances in precision medicine in urologic oncology. At this year's conference, the application of artificial intelligence (AI) and holographic imaging (three-dimensional reconstruction) in robotic surgery emerged as a major focus. Oncology Frontier – UroStream invited Professor Gang Zhu of Beijing United Family Hospital for an interview to discuss the clinical value of AI and holographic imaging, strategies for functional preservation, and the translational challenges involved in moving innovative technologies from demonstration to routine clinical practice.
AIDS 2026 | Interview with Dr. Claire Norcross: Analysis of HIV Drug Resistance Profiles and Implementation Strategies for Long-Acting Antiretroviral Regimens in African Populations
Editorial Note: The 2026 International AIDS Conference (AIDS 2026) was held in Rio de Janeiro, Brazil, covering diverse themes in global HIV/AIDS prevention and treatment. This exclusive interview features…
AIDS 2026 | Adriana Cervo: Focus on Long-Term Survival, Tumor Recurrence and Post-Transplant Metabolic Management Among HIV-Infected Liver Transplant Recipients
The 2026 International AIDS Conference (AIDS 2026) was held in Rio de Janeiro, Brazil. Long-term prognosis of liver transplantation in people living with HIV (PLWH) emerged as a key topic in the hepatology track of the conference. Dr. Adriana Cervo from the University Hospital of Modena, Italy, presented a specialized study at the conference, systematically analyzing long-term survival, rejection episodes, hepatocellular carcinoma (HCC) recurrence and metabolic complications following liver transplantation in PLWH. Her work provides evidence-based references for transplant diagnosis and treatment in this special patient population.
AIDS 2026 | Dr. Bascombe: Moving Beyond BMI to Address Occult Liver Injury in Lean HIV-Associated Fatty Liver Disease
The 2026 International AIDS Conference (AIDS 2026) was held in Rio de Janeiro, Brazil. Bringing together global specialists in infectious diseases, the conference covered a wide array of cutting-edge topics including viral prevention and control, antiretroviral therapy, and long-term health management for people living with HIV, and shared numerous innovative clinical research findings. At the conference, Dr. Florence Bascombe from University College London presented a special study on lean steatotic liver disease (SLD) among people living with HIV. Her discoveries have reshaped established clinical understanding of disease characteristics in patients with lean fatty liver disease, offering new insights into liver disease screening and management for this special population.
AIDS 2026 | Dr. Alfredo Tagarro: Moving Beyond Transmission – In-Depth Exploration of Immune Profiles and Intervention Strategies in HIV-Exposed Infants and Young Children
The 2026 International AIDS Conference (AIDS 2026) was successfully held in Rio de Janeiro, Brazil. The prevention and control of maternal, infant and pediatric HIV remained a key topic of discussion at this conference. We conducted an exclusive interview with Dr. Alfredo Tagarro from the Instituto de Investigación 12 de Octubre, Spain. Breaking free from the conventional analytical framework of mother-to-child transmission, his research proposes an innovative research perspective of “Moving Beyond Transmission”, focusing on immune characteristics, risk triggers and intervention strategies among HIV-exposed infants and young children. The in-depth discussion covers core directions including pediatric immune disparities, gaps in clinical screening, and pre-emptive family interventions, delivering cutting-edge research insights to optimize full-cycle health management for HIV-exposed infants and young children.
2026 Pujiang Urological Oncology Academic Conference丨Professor Dingwei Ye: Reshaping First-Line Treatment for Urothelial Carcinoma — Standardized Comprehensive Management to Maximize Long-Term Patient Benefit
The 2026 Pujiang Urological Oncology Academic Conference was held in Shanghai. In recent years, innovative approaches including antibody-drug conjugates (ADCs), immunotherapy, and precision diagnostics have developed rapidly, shifting the treatment goals of urothelial carcinoma from short-term disease control toward deeper responses, long-term survival, and comprehensive disease management. Enfortumab vedotin-based combination therapy has changed the first-line treatment standard for locally advanced or metastatic urothelial carcinoma (LA/mUC). At the same time, patient selection, standardized treatment, adverse event management, response assessment, and long-term follow-up in real-world practice have become critical to translating evidence-based benefits into meaningful clinical outcomes. Oncology Frontier · UroStream invited Professor Dingwei Ye of Fudan University Shanghai Cancer Center to share his clinical perspectives on first-line treatment transformation, standardized continuous treatment, and advances in perioperative research.